Atlas Trials

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Clinical trial NCT03044730 · UNKNOWN

Trial details

NCT number
NCT03044730
Sponsor
Northwestern University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerTriple-Negative Breast Carcinoma
Start date
2017-05-25
Primary completion
2019-04-24
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.